


CELESTIAL BIOLABS LIMITED

Plot No.59, Road No.12, TSIC Tech Park, IDA Nacharam, Hyderabad-500 076

Statement of Standalone Unaudited Financial Results for the Quarter Ended September,30th 2018

		Rs In Lacs					
SL.NO.	PARTICULARS	Quarter Ended			Halfyear Ended		Previous Year
		30.09.2018 (Unaudited)	30.06.2018 (Unaudited)	30.09.2017 (Unaudited)	30.09.2018 (Unaudited)	30.09.2017 (Unaudited)	31.03.2018 (Audited)
I	Income from operations						
	a) Revenue from operations	1683.51	1669.17	323.22	3352.68	927.95	4281.46
	b) Other Income	0.70	0.00	0.00	0.70	0.00	0.04
	Total income	1684.21	1669.17	323.22	3353.38	927.95	4281.50
II	Expenditure						
	a) Cost of raw and packing materials consumed	5.91	24.49	0.00	30.40	9.41	10.80
	b) Purchase of Traded Products	1230.77	787.81	62.80	2018.58	267.12	2490.61
	c) Changes of Inventories of Finished Goods, Work in Progress and Stock in Trade	20.00	59.98	48.99	79.98	84.60	366.59
	d) Employee Benefits Expense	69.33	29.52	6.25	98.85	21.73	63.40
	e) Depreciation and amortization	188.27	192.58	192.58	380.84	385.16	769.54
	g) Finance Cost	27.85	0.05	0.05	27.90	0.10	2.54
	h) Other Expenses	82.61	447.58	8.45	530.19	20.92	167.16
	Total expenses	1624.74	1542.01	319.12	3166.74	789.04	3870.64
III	Profit / (Loss) before exceptional and extra ordinary items (I-II)	59.47	127.16	4.10	186.64	138.91	410.86
IV	Exceptional items	0.00	0.00	0.00	0.00	0.00	0.00
V	Profit / (Loss) before tax (III - IV)	59.47	127.16	4.10	186.64	138.91	410.86
VI	Tax expense	0.00	0.00	0.00	0.00	25.69	78.29
VII	Net Profit / (Loss) for the period (V-VI)	59.47	127.16	4.10	186.64	113.22	332.57
VIII	Other Comprehensive Income, Total Other Comprehensive Income, net of Tax	0.00	0.00	0.00	0.00	0.00	13.06
IX	Total Comprehensive Income for the period	59.47	127.16	4.10	186.64	113.22	345.63
X	Paid-up Equity Share Capital (Face Value of Rs.10/- per share)	2258.63	2258.63	2258.63	2258.63	2258.63	2258.63
XI	Earning Per Share for the Period						
	Basic	0.26	0.56	0.02	0.83	0.50	1.53
	Diluted	0.26	0.56	0.02	0.83	0.50	1.53


For CELESTIAL BIOLABS LIMITED


Chairman & Managing Director

Notes

- 1) The Statement has been reviewed by the Audit Committee and approved by the Board of Directors at it's meeting held on 14.11.2018
- 2) Financial Results for all the periods presented have been prepared in accordance with the recognition and measurement Principles of Ind AS notified under the Companies (Indian Accounting Standards) Rules , 2015 as amended from time to time.
- 3) The Company is engaged in the business of "Formulations" and therefore, has only one reportable segment in accordance with Ind AS 108 " Operating Segment".
- 4) The Financial results and other financial information for the quarter ended 30th September,2018 has been compiled by the management as per Ind AS, after excercising necessary due deligence , to ensure that the financial results provide true and fair view of the results in accordance with Ind AS. This information has not been subject to any limited review or audit.
- 5) No Investor Complaints were received for Quarter Ended 30th September,2018
- 5) The Financial results of the Company for the Quarter Ended 30th September, 2018 have been filed with the National Stock Exchange of India Limited (NSE) and Bombay Stock Exchange Limited (BSE) and are available in Company's website www.celestialbiolabs.com

HYDERABAD
Date: 14.11.2018

For CELESTIAL BIOLABS LIMITED

Chairman & Managing Director
MANAGING DIRECTOR

CELESTIAL BIOLABS LIMITED
Plot No.59, Road No.12, TSIIC Tech Park, IDA Nacharam, Hyderabad-500 076
Standalone Unaudited Assets and Liabilities

(In Lakhs)

PARTICULARS	AS AT 30.09.2018 (Unaudited)	AS AT 31.03.2018 (Audited)
I. ASSETS		
1) Non-Current Assets	1,265.91	1,284.34
a) Property , Plant & Equipment	2,955.81	2,955.81
b) Capital Work-in-Progress	4,448.38	4,025.55
c) Other Intangible Assets		
d) Financial Assets	30.10	30.10
i) Investments	-	-
ii) Trade Receivables	-	-
iii) Loans	-	-
e) Deferred Tax Assets (Net)	-	-
f) Other Non-Current Assets	-	-
	8,700.20	8,295.79
2) Current Assets	291.30	395.77
a) Inventories		
b) Financial Assets	-	-
i) Investments	2,778.96	2,076.91
ii) Trade Receivables	2.03	0.99
iii) Cash & Cash Equivalent	-	-
iv) Bank Balance other than (iii) above	67.69	67.69
v) Loans	-	-
vi) Other Financial Assets	70.05	558.30
c) Other Current Assets	3,210.03	3,099.66
	11,910.23	11,395.45
TOTAL ASSETS		
II. EQUITY AND LIABILITIES		
Equity -	2,258.63	2,258.63
a) Equity Share Capital	8,158.11	7,971.47
b) Other Equity		
	10,416.74	10,230.10
TOTAL EQUITY		
Liabilities		
a) Non-Current Liabilities		
i) Financial Liabilities	1,239.00	942.00
1) Other Long Time Liabilities	(2.65)	(2.65)
ii) Provisions	1,236.35	939.35
Total Non-Current Liabilities		
b) Current Liabilities		
i) Financial Liabilities	34.38	43.36
1) Trade Payables	-	-
2) Other Financial Liabilities	57.98	27.59
ii) Other Current Liabilities	164.78	155.05
iii) Provisions	257.14	226.00
Total Current Liabilities	1,493.49	1,165.35
Total Liabilities		
	11,910.23	11,395.45
TOTAL EQUITY AND LIABILITIES		

For CELESTIAL BIOLABS LIMITED


Chairman & Managing Director



B V SWAMI & CO.,
CHARTERED ACCOUNTANTS

Flat No. 101, Sridevi Apartments,
Hindi Nagar Colony, Punjagutta,
Hyderabad - 500 082.

Ph : 040-23350300

E-mail : cachandrasekharv@gmail.com
girishputha@gmail.com

LIMITED REVIEW REPORT

To,
The Board Members of
Celestial Biolabs Limited

We have reviewed the accompanying "Statement of unaudited standalone financial results of M/s Celestial Biolabs Limited for the period ended 30th September, 2018", being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 05, 2016.

The Preparation of Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, interim financial reporting (Ind AS 34) prescribed under Section 133 of the Companies Act, 2013 read with rule 3 of Companies (Indian Accounting Standards) Rules, 2015 and read with SEBI Circular NO. CIR/CFD/FAC/62/2016 dated July 05, 2016 is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these Financial Statements based on our review.

We Conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial information performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is Limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an Audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited Financial Results, prepared in accordance with applicable accounting standards specified under section 133 of the Companies Act, 2013 read with rule 7 of the Companies (Accounts) Rules, 2014, and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 including the manner in which it is to be disclosed or that it contains any material misstatement.

For B V Swami & Co.,
Chartered Accountants
Firm Reg No. 009151S


CA. Chandrasekhar V
Partner
M.No. 223399



Place : Hyderabad
Date : 14.11.2018